Tempest Therapeutics, Inc.
TPSTAnalyst Consensus
Rating Trend
Recent Rating Actions
| Firm | Action | Rating | Date |
|---|---|---|---|
| HC Wainwright & Co. | maintain | Buy | Sep 24, 2026 |
| HC Wainwright & Co. | upgrade | Neutral →Buy | Jan 22, 2026 |
| HC Wainwright & Co. | downgrade | Buy →Neutral | Apr 10, 2025 |
| Scotiabank | downgrade | Sector Outperform →Sector Perform | Apr 10, 2025 |
| Scotiabank | maintain | Sector Outperform | Mar 28, 2025 |
| HC Wainwright & Co. | maintain | Buy | Mar 28, 2025 |
| Piper Sandler | maintain | Overweight | Nov 13, 2024 |
| HC Wainwright & Co. | maintain | Buy | Nov 13, 2024 |
| HC Wainwright & Co. | maintain | Buy | Oct 10, 2024 |
| HC Wainwright & Co. | maintain | Buy | Aug 15, 2024 |
| Piper Sandler | maintain | Overweight | Jun 21, 2024 |
| HC Wainwright & Co. | maintain | Buy | Jun 20, 2024 |
| HC Wainwright & Co. | maintain | Buy | May 13, 2024 |
| HC Wainwright & Co. | maintain | Buy | May 10, 2024 |
| HC Wainwright & Co. | maintain | Buy | Mar 20, 2024 |
| HC Wainwright & Co. | maintain | Buy | Mar 12, 2024 |
| HC Wainwright & Co. | maintain | Buy | Oct 11, 2023 |
| HC Wainwright & Co. | maintain | Buy | Aug 11, 2023 |
| HC Wainwright & Co. | maintain | Buy | Jun 5, 2023 |
| HC Wainwright & Co. | maintain | Buy | May 30, 2023 |
| HC Wainwright & Co. | maintain | Buy | May 11, 2023 |
| Ladenburg Thalmann | maintain | Buy | Apr 28, 2023 |
| HC Wainwright & Co. | maintain | Buy | Mar 23, 2023 |
| Piper Sandler | maintain | Overweight | Mar 23, 2023 |
| HC Wainwright & Co. | maintain | Buy | Feb 8, 2023 |
Earnings History
Next report: Nov 11, 2026 · EPS est. $-0.32| Report Date | EPS Actual | EPS Est. | Revenue Actual | Revenue Est. |
|---|---|---|---|---|
| Aug 13, 2026 | $-0.34 | $-0.30 | — | — |
| May 14, 2026 | $-2.53 | $-0.28 | — | — |
| Mar 31, 2026 | $-0.62 | $-0.62 | — | — |
| Nov 5, 2025 | $-0.79 | $-3.27 | — | — |
| Aug 11, 2025 | $-2.07 | $-3.23 | — | — |
| May 13, 2025 | $-3.16 | $-3.71 | — | — |
| Mar 27, 2025 | $-4.03 | $-3.12 | — | — |
| Nov 12, 2024 | $-5.33 | $-4.81 | — | — |
News
BRISBANE, Calif., Oct. 14, 2026 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST) (“Tempest”), a clinical-stage biotechnology company developing in vivo CAR-T therapies designed to reset dysfunctional immunity in cancer and autoimmune disease, today announced that John W.
What happened Tempest Therapeutics, Inc. (NASDAQ: TPST) said on September 22, 2026, that it signed a Master Services Agreement with Factor Bioscience Inc. The agreement covers research and development services under work orders that both sides approve. Tempest said Work Order No. 1 covers in vivo CAR-T therapies. Effective September 22, 2026, the board appointed
BRISBANE, Calif., Sept. 23, 2026 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST) (“Tempest”), a clinical-stage biotechnology company developing in vivo CAR-T therapies designed to reset dysfunctional immunity in cancer and autoimmune disease, today announced that Nancy Freda-Smith has been appointed to its board of directors and will serve as Chair of the Audit Committee.
Shares of Tempest Therapeutics Inc (NASDAQ:TPST) rose sharply in pre-market trading after the California-based clinical-stage biotechnology company announced an exclusive option agreement with Hebei Senlang Biotechnology Co., Ltd.
-Transaction complements Tempest's existing CD7-targeted lipid nanoparticle in vivo CAR-T delivery platform, which is planned to enter the clinic later this year
$2.5 million upfront with up to approximately $5 million of potential aggregate gross proceeds upon the exercise in full of warrants $2.5 million upfront with up to approximately $5 million of potential aggregate gross proceeds upon the exercise in full of warrants
BRISBANE, Calif., Sept. 08, 2026 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST) (“Tempest”), a clinical-stage biotechnology company pioneering the development of advanced in vivo CAR-T therapies for cancer and autoimmune disease, today announced that Matt Angel, Ph.D.
Executed a development collaboration with Senlang Biotechnology to advance certain in vivo CAR-T product candidates, including TPST-4003, a CD7-targeted next-generation in vivo CAR-T, with first patient dosing anticipated in the fourth quarter of 2026 and initial clinical data expected in the first half of 2027